✦ LIBER ✦

A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma

✍ Scribed by Lisa N. Abaid, John P. Micha, Mark A. Rettenmaier…

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of modified dose-dense

✍ L. Abaid; J. Micha; M. Rettenmaier; J. Brown; A. Mendivil; K. Lopez; B. Goldstei 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

A phase II study of cetuximab/paclitaxel

✍ Jason Konner; Russell J. Schilder; Felicia A. DeRosa; Scott R. Gerst; William P. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 226 KB

A phase II study of outpatient first-lin

✍ J.P. MICHA; B.H. GOLDSTEIN; M.A. RETTENMAIER; M. GENESEN; C. GRAHAM; K. BADER; K 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Long-term results of dose-dense paclitax

✍ Katsumata, Noriyuki; Yasuda, Makoto; Isonishi, Seiji; Takahashi, Fumiaki; Michim 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 326 KB

A phase II study of ramucirumab (IMC-112

✍ Penson, Richard T.; Moore, Kathleen M.; Fleming, Gini F.; Braly, Patricia; Schim 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 637 KB

A phase II evaluation of belinostat and

✍ Don S. Dizon; John A. Blessing; Richard T. Penson; Richard D. Drake; Joan L. Wal 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 197 KB